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Abstract 
Introduction: Clostridium innocuum is an anaerobic Gram-positive bacterium, unable to produce toxins and rarely 
causes infections. We report the first case of C. innocuum osteomyelitis and bacteremia in a patient with acute 
lymphoblastic leukemia (ALL). Findings were compared with previously reported cases of C. innocuum infections 
in immunocompromised patients, e.g., patients with acquired immune deficiency syndrome, leukemia, and organ 
transplantation.
Case description: A 32-year-old Japanese male was admitted for persistent low-grade fever and purpura lasting for 
1 month. Complete blood counts and cytogenetic analysis identified Ph1-positive ALL, which was successfully treated 
using chemotherapy. However, the patient developed high fever and lumbar pain during complete remission. Fluoro-
deoxyglucose-positron emission tomography and computed tomography demonstrated osteomyelitis. C. innocuum 
was identified as the causative agent and the patient was successfully treated using antibiotic therapy.
Discussion and evaluation: We performed a literature review revealing a number of common aspects to the clinical 
presentation of C. innocuum infection and an association with various comorbidities. Further, we highlight the most 
efficient diagnostic and treatment strategies for C. innocuum osteomyelitis.
Conclusions: Clostridium innocuum can be a causative pathogen of osteomyelitis and bacteremia in immunocom-
promised patients.
Keywords: Clostridium innocuum, Acute lymphoblastic leukemia, Osteomyelitis, Direct 16S-rRNA sequencing, 
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Introduction
Clostridial species are common anaerobic, spore-form-
ing, Gram-positive bacteria found in the normal flora of 
the oropharynx and gastrointestinal tract. Among them, 
Clostridium innocuum is an unusual cause of infections 
in humans. A few reports have described bacteremia 
due to C. innocuum in immunocompromised patients, 
such as those with acquired immune deficiency syn-
drome (AIDS), leukemia, and organ transplantation. 
Because C. innocuum has intrinsic resistance to sev-
eral common antibiotics, including vancomycin, it may 
cause intractable infections (Alexander et  al. 1995; 
David et  al. 2004). We report the first case of pelvic 
osteomyelitis and sepsis due to C. innocuum infection 
in a patient with acute lymphocytic leukemia (ALL). 
We performed a literature review of previous reports 
to determine the most appropriate diagnostic strategies 
and treatment regimens in cases of C. innocuum infec-
tion in patients with distinct comorbidities.
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Case description
A 32-year-old Japanese male with no previous medical 
history was admitted to our hospital for a persistent low-
grade fever and purpura lasting for 1 month. A complete 
blood count (CBC) revealed marked anemia, thrombo-
cytopenia, and hyperleukocytosis (136,130/µL; blasts 
97%, neutrophils 0%, lymphocytes 2%, and eosinophils 
1%). Bone marrow aspiration from iliac crest were hyper-
cellular with 97.6% lymphoblasts. Cytogenetic analysis 
revealed that blasts were positive for the Philadelphia 
chromosome (Ph1) with minor BCR/ABL mRNA tran-
scripts. Therefore, the patient was diagnosed with Ph1-
positive ALL.
Combination chemotherapy with dasatinib was imme-
diately initiated as remission induction. On treatment 
day 27, CBCs had normalized and bone marrow aspira-
tion from iliac crest analysis confirmed complete remis-
sion. On treatment day 39, consolidation chemotherapy 
with daunorubicin, cyclophosphamide, vincristine, pred-
nisolone, methotrexate, and dasatinib was initiated. On 
treatment day 51, the patient became pyrexial (39.2°C) 
and reported severe lower back pain. The pain rapidly 
worsened and radiated to the right axilla. WBC count 
was 430/mm3, with 8% segmented neutrophils, 2% bands, 
80% lymphocytes, and 10% monocytes. We immediately 
collected blood culture and started empiric antibiotic 
therapy with meropenem, vancomycin, and liposomal 
amphotericin B. CT imaging revealed no apparent abnor-
mal findings; however, fluorodeoxyglucose (18F)-
positron emission tomography (FDG-PET) revealed 
increased uptake of FDG in the iliac bones and right side 
of the sacrum. These findings suggested osteomyelitis 
of the iliac bone and sacrum and Gram-positive bacte-
ria were detected by needle aspiration biopsy of the iliac 
bone (Fig.  1). Gram-positive bacterium was also found 
in the blood culture; however, the bacteria could not be 
identified. For this reason, we tested the blood culture for 
direct 16S ribosomal RNA (16S rRNA) sequencing and 
identified C. innocuum 2 days later. The presence of this 
pathogen was also confirmed by bone marrow culture 
from iliac crest. As a result of these findings, the patient 
was treated with piperacillin/tazobactam, metronidazole, 
and clindamycin. In this case, the causative pathogen was 
sensitive to ampicillin, piperacillin/tazobactam, mero-
penem, clindamycin, and metronidazole. Intermediate 
sensitivity to penicillin G and cefmetazole was observed. 
Further, the isolated strain was resistant to vancomycin 
with a minimum inhibitory concentration (MIC) of 8 μg/
mL.
Fever gradually resolved over the next 3  weeks, but 
the lumbar pain persisted. CT imaging identified a small 
abscess in the iliacus muscle. Therefore, CT-guided 
drainage was performed. No pathogens were detected 
in cultures of the abscess fluid or blood. The previ-
ously administered antibiotic regimen was consequently 
deemed effective. After another 8  weeks of antibiotic 
therapy, the lumbar pain subsided and treatment was ter-
minated. On treatment day 104, the patient was asympto-
matic and chemotherapy was reinitiated.
Discussion and evaluation
We identified previously published cases of C. innocuum 
infection by conducting a PubMed search of the literature 
using the following keywords: Clostridium innocuum; 
ALL; osteomyelitis; and anaerobic bacteria. PubMed que-
ries also included infections that developed in immuno-
compromised patients during chemotherapy.
The first human case of C. innocuum infection was 
reported in the 1960s (Smith and King 1962). The term 
“innocuum” is derived from “innocuous” (i.e., meaning 
innocent) as the organism lacks the ability to produce 
Fig. 1 Diagnostic approach for a 32-year-old male with Clostridium innocuum osteomyelitis. a (18F)-Fluorodeoxyglucose positron emission tomog-
raphy (FDG-PET) revealed marked uptake of FDG in the sacroiliac joint and iliac bone. b Bone marrow biopsy from iliac crest confirmed C. innocuum 
infection (Grambiopsy conf1000).
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toxins. A PubMed search of the literature identified 
16 previously reported cases of C. innocuum infection 
(Smith and King 1962; Castiglioni et  al. 2003; Crum-
Cianflone 2009; Hung et al. 2014; Bodey et al. 1991; Cut-
rona et  al.1995). Details of these cases are summarized 
in Additional file  1: Table S1. Median age of patients 
was 38.0 years, and 66.7% were male. All but one patient 
had a comorbid disorder, namely acute leukemia, AIDS, 
chronic hepatitis, genitourinary malignancy, gastro-
intestinal malignancy, or organ transplantation (Crum-
Cianflone 2009; Hung et  al. 2014; Bodey et  al. 1991; 
Cutrona et al. 1995; Shah et al. 2009). The most common 
clinical symptom was fever of unknown origin followed 
by the gastrointestinal tract disorder, such as diarrhea 
or constipation, and/or respiratory disorder. Almost all 
patients developed bacteremia. Most commonly used 
agents were piperacillin/tazobactam, metronidazole, and 
clindamycin to which C. innocuum appeared susceptible. 
Nevertheless, the prognosis of these patients was poor, 
with a mortality rate of 33.3%.
The diagnosis of anaerobic infections is clinically 
challenging. Detection rates from blood cultures are 
extremely low (approximately 4.0%), mainly because 
of the slow growth of anaerobic bacteria. In addition, a 
number of anaerobic bacteria species are part of the nor-
mal microbiota in humans and concomitant infection 
with aerobic bacteria is common (Cockerill et  al. 1997). 
One study in patients with blood cultures positive for 
anaerobic bacteria demonstrated patients who received 
appropriate anti-anaerobic antibiotics as the initial treat-
ment, or who were immediately changed to appropriate 
antibiotics following identification of the causative path-
ogen, had markedly improved prognosis compared with 
patients who did not receive appropriate antibiotic treat-
ment (Salonen et al. 1998).
Direct 16S ribosomal RNA gene sequencing has 
recently been developed, allowing the composition of 
microbial communities to be analyzed. In the present 
case, this approach identified C. innocuum in blood cul-
tures within a few days of admission and that allowed 
the selection of an appropriate initial antibiotic regimen. 
Therefore, direct 16S ribosomal RNA gene sequenc-
ing may be useful in the early detection of Clostridium 
species in clinical samples (Drancourt et al. 2000; Mory 
et al. 1998). Unlike C. difficile, C. innocuum is suscepti-
ble to penicillin, clindamycin, and metronidazole but not 
to vancomycin (Ackermann et  al. 2001; Goldstein et  al. 
2014). Our patient was successfully treated by a 8-week 
combination antibiotic therapy comprising piperacillin/
tazobactam, clindamycin, and metronidazole. There is 
currently no standard duration of treatment for C. innoc-
uum infections. However, 4–6  weeks with appropriate 
antibiotics and debridement is generally recommended 
for the treatment of osteomyelitis (Howard et  al. 1994; 
Spellberg and Lipsky 2012).
Comprehensive blood and bone marrow aspiration 
analysis revealed Ph1-positive ALL in our patient war-
ranting immediate initiation of systemic chemotherapy. 
The patient developed high fever and back pain, although 
complete remission of ALL was achieved. Therefore, we 
suspected that these symptoms were due to an infection 
rather than related to a lymphoproliferative disease.
Systemic chemotherapy has been reported to induce 
neutropenic enterocolitis (NEC), a common complica-
tion in neutropenic cancer patients (Nesher and Rolston 
2013). Symptoms generally develop after the third week 
of chemotherapy and include neutropenic fever and 
abdominal pain (mainly in the right lower abdomen). 
The diagnostic criteria for NEC is neutropenia (abso-
lute neutrophil count <500  ×  106  cells/L), bowel wall 
thickening >4 mm, and high fever with the exclusion of 
other diagnoses. The mortality of NEC patients is rela-
tively high (>60%). Risk factors for NEC include acute 
leukemia, lymphoma, solid tumor, and neutropenia in 
addition to cytotoxic chemotherapeutic agents such as 
cytosine arabinoside, anthracyclines, and taxanes. In this 
case, the patient complained of abdominal distention 
and constipation after consolidation chemotherapy was 
started. Computed tomography (CT) revealed marked 
constipation and edematous intestinal wall, findings that 
were compatible with NEC. Therefore, we believed that 
bacterial translocation of C. innocuum occurred from the 
damaged intestinal tract to the iliac bone.
According to identified case reports of C. innocuum, 
previous C. difficile associated diarrhea (CDAD) may 
predispose to C. innocuum bacteremia (Crum-Cianflone 
2009); however, C. difficile infection was not detected 
in our case. NEC without CDAD may induce bacte-
rial translocation of C. innocuum from the enteral flora. 
Osteomyelitis due to Clostridium species is quite rare. 
In the previously reported articles on osteomyelitis due 
to C. difficile, C. clostridioforme, C. celerecrescens, C. 
bifermentans, and C. septicum, several have reported an 
association with trauma (Mischnik et al. 2011; Al-Najjar 
et al. 2013; Scanlan et al. 1994). The treatment that was 
most commonly chosen was metronidazole, clindamycin, 
or β-lactam. Almost all anaerobic osteomyelitis occur by 
direct extension from an adjacent focus of infection and 
are rarely due to bacteremia; however, in the present 
case, the bacteria may have reached from the intestinal 
tract to the iliac bone via blood circulation.
Immunodeficiency may contribute to the progres-
sion of infection. As pathogens are difficult to identify, 
treatments generally include broad spectrum antibiotics 
covering rare anaerobic bacteria and antifungal agents. 
Surgical intervention is recommended only in cases of 
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bowel perforation or necrosis. The recommended dura-
tion of antibiotic therapy is from 4  weeks to 6  months. 
For immunosuppressed patients, the recommended 
treatment is more than 8 weeks. Further, it is considered 
that less than 4 weeks of antibiotic therapy is a risk factor 
for recurrence in patients who have undergone surgical 
management (Pigrau et al. 2015;  Lima et al. 2014).
Conclusions
In conclusion, we report a rare case of osteomyelitis and 
bacteremia due to C. innocuum. Although C innocuum 
lacks the ability to produce toxins and has weak patho-
genicity, it may cause severe infections in immunocom-
promised patients, such as those with acute leukemia, 
chronic viral hepatitis, or HIV.
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